Q. Cai

Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial

Yang Yao, X. Niu, C. Tu, 2022, Frontiers in Oncology.

Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial.

Jingnan Shen, Gang Huang, J. Chen, 2018 .

Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study

Gang Huang, Baocheng Wang, Yuankai Shi, 2020, Clinical Cancer Research.

A novel homozygous DOCK8 mutation associated with unusual coexistence of gross molluscum contagiosum and epidermodysplasia verruciformis in a DOCK8 deficiency patient

X. Mo, J. Chen, B. Wang, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Evaluation of hypertension and hand-foot syndrome as markers of anlotinib efficacy in advanced soft tissue sarcoma.

Y. Yao, J. Song, Y. Lu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)

J. Song, Jingxian Shen, Yang Yao, 2019, Annals of Oncology.

A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.

Yang Yao, X. Niu, C. Tu, 2020 .